A detailed history of Paradigm Biocapital Advisors LP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,516,686 shares of CRNX stock, worth $136 Million. This represents 4.63% of its overall portfolio holdings.

Number of Shares
2,516,686
Previous 2,513,302 0.13%
Holding current value
$136 Million
Previous $113 Million 14.2%
% of portfolio
4.63%
Previous 4.56%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$43.83 - $54.98 $148,320 - $186,052
3,384 Added 0.13%
2,516,686 $129 Million
Q2 2024

Aug 14, 2024

SELL
$42.12 - $51.91 $25.8 Million - $31.7 Million
-611,447 Reduced 19.57%
2,513,302 $113 Million
Q1 2024

May 15, 2024

BUY
$34.76 - $46.81 $28.2 Million - $38 Million
811,830 Added 35.1%
3,124,749 $146 Million
Q4 2023

Feb 14, 2024

BUY
$25.62 - $37.07 $3.44 Million - $4.97 Million
134,182 Added 6.16%
2,312,919 $82.3 Million
Q3 2023

Nov 14, 2023

BUY
$15.97 - $30.59 $12.5 Million - $24 Million
783,735 Added 56.18%
2,178,737 $64.8 Million
Q2 2023

Aug 14, 2023

BUY
$15.73 - $23.6 $4.11 Million - $6.16 Million
261,220 Added 23.04%
1,395,002 $25.1 Million
Q1 2023

May 15, 2023

BUY
$15.31 - $21.1 $3.73 Million - $5.14 Million
243,677 Added 27.38%
1,133,782 $18.2 Million
Q4 2022

Feb 14, 2023

BUY
$15.49 - $19.05 $5.74 Million - $7.06 Million
370,849 Added 71.42%
890,105 $16.3 Million
Q3 2022

Nov 14, 2022

BUY
$18.11 - $22.37 $9.4 Million - $11.6 Million
519,256 New
519,256 $10.2 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.9B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Paradigm Biocapital Advisors LP Portfolio

Follow Paradigm Biocapital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.